Country of Operation
Target income level
- Lower-middle income (20-40%)
- Middle-income (40-60%)
- Higher middle-income (60-80%)
- High-income (80-100%)
- Noncommunicable disease(s)
SummaryGlicOnLine is a diabetes treatment automation service for all diabetes types and therapeutic stages. Android-internet based, clinically tested to improve glycemic control and QoL, GlicOnLine empowers patients to correctly follow treatment, while improving disease manageability with alarms and data.
The company's mission is to improve the quality of life of patients with diabetes.
Key program components
In 2002, Floro Dória designed a software that allowed for a quicker calculation of insulin dosage. The goal of this automation was to reduce barriers such as difficulty calculating proportions/insulin amounts and, therefore, increase the number of users who take advantage of this technology. The information collected by the software was input into an electronic system that allowed easy calculation of insulin dosage. Clients had an online electronic medical record profile, and could, at any given time, log into the system to determine their glycemic index, calculate nutrients intake, and choose food from a menu. The program calculated carbohydrates and fat content, and indicated back the amount of insulin that must be administered. The software allowed doctors to monitor their patients online and change treatment parameters whenever necessary. Any prescription changes were automatically sent to the patients mobile phone.
GlicOnLine was incorporated in 2004, and received funding from the São Paulo Research Foundation (FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo) to incubate the business and develop the software. In 2006 the software was ready, and was clinically testested at the Clinical Hospital of the University of São Paulo. Results showing GlicOnLine's effect on glycemic control and patients´ QoL, were presented at the 13th International Endocrinology Congress (2008).
GlicOnLine was finally launched as freeware for patients and doctors in August of 2009. In 2012, again with FAPESP support, GlicOnLine was migrated to Android, extending its functionalities to include medicament, diets and fixed dose insulin support, thus enabling treatment automation for all diabetes types and therapeutic stages.
Multi professional teams are supported, and follow-up data is presented in graphs and tables specially designed to facilitate medical analysis. Alarms and reports for both health teams and management enable greater effectiveness, as well as pay for performance, reimbursement and optimized supply distribution schemes.
The new GlicOnLine was introduced in November, 2012, at the Brazilian Endocrinology Congress. In April 2013,after a 6 months long beta test operation, distribution started through GooglePlay, reaching 500 users in Dec 2013.
In November, 2013 a new multicentric trial was started, to evaluate GlicOnLine´s impact in public health patients. Three units (primary, secondary and tertiary levels) in three cities will use GlicOnLine and gather evidence of its impact on glycemic control and QoL.
In January, 2014, Quasar joined the Samsung Enterprise Alliance Program (SEAP).
Dr Karla Mello, PhD - a researcher, educator and physician, who also has diabetes - is one of the partners of GlicOnLine, and one of the most respected specialists in Diabetes in Brazil. .